中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2014年
6期
495-499
,共5页
尹珍珍%易俊林%黄晓东%罗京伟%王凯%高黎%曲媛%张世平%肖建平
尹珍珍%易俊林%黃曉東%囉京偉%王凱%高黎%麯媛%張世平%肖建平
윤진진%역준림%황효동%라경위%왕개%고려%곡원%장세평%초건평
鼻咽肿瘤/放射疗法%鼻咽肿瘤/化学疗法%鼻咽肿瘤/分子靶向疗法%预后
鼻嚥腫瘤/放射療法%鼻嚥腫瘤/化學療法%鼻嚥腫瘤/分子靶嚮療法%預後
비인종류/방사요법%비인종류/화학요법%비인종류/분자파향요법%예후
Nasopharyngeal neoplasms/radiotherapy%Nasopharyngeal neoplasms/chemotherapy%Nasopharyngeal neoplasms/targeted molecular therapy%Prognosis
目的 回顾性对比IMRT同期EGFR单抗、同期化疗和单纯IMRT治疗鼻咽癌的疗效及不良反应.方法 将2008-2012年间收治的68例接受IMRT同期EGFR单抗的Ⅱ—Ⅳb期初治鼻咽癌患者纳入BRT组,应用SAS软件进行1∶2配对形成单纯IMRT (IMRT)组136例及同期放化疗(CCRT)组136例,共340例.Kaplan-Meier法计算生存率并Logrank检验,Cox模型分析预后因素.结果 BRT、IMRT、CCRT组3年样本数分别为14、69、47例.全组3年OS、DFS、LRC、DMFS分别为91.2％、80.2％、93.1％、87.2％.BRT、IMRT、CCRT组的3年OS分别为91.9％、92.1％、89.9％(P=0.379),3年DFS分别为82.1％、77.9％、81.6％ (P=0.594),3年LRCR分别为98.2％、90.6％、93.0％ (P =0.249),3年DMFS分别为85.2％ 、85.2％、90.3％ (P=0.383).多因素分析提示T分期及同期EGFR单抗是LRC的影响因素(P=0.034、0.032).结论 鼻咽癌单纯IMRT即可达较好疗效.三组之间整体疗效相近,但BRT组有提高LRC的趋势.
目的 迴顧性對比IMRT同期EGFR單抗、同期化療和單純IMRT治療鼻嚥癌的療效及不良反應.方法 將2008-2012年間收治的68例接受IMRT同期EGFR單抗的Ⅱ—Ⅳb期初治鼻嚥癌患者納入BRT組,應用SAS軟件進行1∶2配對形成單純IMRT (IMRT)組136例及同期放化療(CCRT)組136例,共340例.Kaplan-Meier法計算生存率併Logrank檢驗,Cox模型分析預後因素.結果 BRT、IMRT、CCRT組3年樣本數分彆為14、69、47例.全組3年OS、DFS、LRC、DMFS分彆為91.2％、80.2％、93.1％、87.2％.BRT、IMRT、CCRT組的3年OS分彆為91.9％、92.1％、89.9％(P=0.379),3年DFS分彆為82.1％、77.9％、81.6％ (P=0.594),3年LRCR分彆為98.2％、90.6％、93.0％ (P =0.249),3年DMFS分彆為85.2％ 、85.2％、90.3％ (P=0.383).多因素分析提示T分期及同期EGFR單抗是LRC的影響因素(P=0.034、0.032).結論 鼻嚥癌單純IMRT即可達較好療效.三組之間整體療效相近,但BRT組有提高LRC的趨勢.
목적 회고성대비IMRT동기EGFR단항、동기화료화단순IMRT치료비인암적료효급불량반응.방법 장2008-2012년간수치적68례접수IMRT동기EGFR단항적Ⅱ—Ⅳb기초치비인암환자납입BRT조,응용SAS연건진행1∶2배대형성단순IMRT (IMRT)조136례급동기방화료(CCRT)조136례,공340례.Kaplan-Meier법계산생존솔병Logrank검험,Cox모형분석예후인소.결과 BRT、IMRT、CCRT조3년양본수분별위14、69、47례.전조3년OS、DFS、LRC、DMFS분별위91.2％、80.2％、93.1％、87.2％.BRT、IMRT、CCRT조적3년OS분별위91.9％、92.1％、89.9％(P=0.379),3년DFS분별위82.1％、77.9％、81.6％ (P=0.594),3년LRCR분별위98.2％、90.6％、93.0％ (P =0.249),3년DMFS분별위85.2％ 、85.2％、90.3％ (P=0.383).다인소분석제시T분기급동기EGFR단항시LRC적영향인소(P=0.034、0.032).결론 비인암단순IMRT즉가체교호료효.삼조지간정체료효상근,단BRT조유제고LRC적추세.
Objective To compare the treatment outcomes and toxicities in nasopharyngeal carcinoma patients who receive intensity-modulated radiotherapy (IMRT) combined with epidermal growth factor receptor (EGFR) monoclonal antibody,IMRT with concurrent chemotherapy,and IMRT alone.Methods Sixty-eight previously untreated patients with stage Ⅱ-Ⅳb nasopharyngeal carcinoma (NPC) who received IMRT combined with cetuximab or nimotuzumab from January 2008 to September 2012 were included in BRT group; the BRT group was matched with 136 patients treated with concurrent chemoradiotherapy (CCRT) and 136 patients treated with IMRT alone at a ratio of 1:2 using SAS software.The Kaplan-Meier method was used for calculating survival rates,and the log-rank test was used for survival difference analysis.Prognostic factors were analyzed by the Cox model.Results The sample sizes of the BRT group,IMRT group,and CCRT group were 14,69,47,respectively.The 3-year overall survival (OS),disease-free survival (DFS),locoregional control (LRC),and distant metastasis-free survival (DMFS) of all patients were 91.2％,80.2％,93.1％,and 87.2％,respectively.The 3-year OS rates of BRT group,IMRT group,and CCRT group were 91.9％,92.1％,and 89.9％,respectively (P=0.379) ;the 3-year DFS rates of BRT group,IMRT group,and CCRT group were 82.1％,77.9％,and 81.6％,respectively (P =0.594) ;the 3-year LRC rates of BRT group,IMRT group,and CCRT group were 98.2％,90.6％,and 93.0％,respectively (P =0.249);the 3-year DMFS rates of BRT group,IMRT group,and CCRT group were 85.2％,85.2％,and 90.3％,respectively (P =0.383).Multivariate prognostic analysis showed that T stage and concurrent use of EGFR monoclonal antibody were influential factors for LRC (P =0.034 and 0.032).Conclusions IMRT alone yields a good treatment outcome in NPC patients.Although there were no significant differences in OS between the three groups,the BRT group showed an increasing trend in LRC.
